Core Viewpoint - Knight-Swift Transportation Holdings is expected to report a year-over-year increase in earnings despite lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is anticipated on April 23, 2025, with an expected EPS of $0.25, reflecting a +108.3% change year-over-year, while revenues are projected at $1.81 billion, down 0.9% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 12.49% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Knight-Swift is lower than the consensus estimate, resulting in an Earnings ESP of -2.25% [10][11]. Historical Performance - Knight-Swift has beaten consensus EPS estimates in two out of the last four quarters, with a recent surprise of +9.09% when it reported earnings of $0.36 against an expectation of $0.33 [12][13]. Investment Considerations - The combination of a negative Earnings ESP and a Zacks Rank of 4 indicates challenges in predicting an earnings beat for Knight-Swift, suggesting that investors should consider additional factors before making investment decisions [11][16].

Core Viewpoint - The market anticipates a year-over-year decline in Masco's earnings due to lower revenues, with a focus on how actual results will compare to estimates [1][3]. Earnings Expectations - Masco is expected to report quarterly earnings of $0.92 per share, reflecting a -1.1% change year-over-year, and revenues are projected at $1.84 billion, down 4.7% from the previous year [3]. - The consensus EPS estimate has been revised 1.36% lower in the last 30 days, indicating a bearish sentiment among analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Masco is lower than the consensus estimate, resulting in an Earnings ESP of -0.82% [10][11]. - A negative Earnings ESP reading, combined with a Zacks Rank of 4, complicates the prediction of an earnings beat for Masco [11]. Historical Performance - In the last reported quarter, Masco was expected to post earnings of $0.88 per share but delivered $0.89, resulting in a surprise of +1.14% [12]. - Over the past four quarters, Masco has beaten consensus EPS estimates three times [13]. Conclusion - Masco does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Peapack-Gladstone (PGC) due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2] Earnings Expectations - The consensus EPS estimate for Peapack-Gladstone is $0.51 per share, reflecting a +6.3% change year-over-year, while revenues are expected to reach $63.49 million, up 19.6% from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 0.81% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4][10] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a negative Earnings ESP of -6.93% for Peapack-Gladstone, suggesting analysts have become bearish on the company's earnings outlook [11][10] Historical Performance - In the last reported quarter, Peapack-Gladstone exceeded the expected EPS of $0.47 by delivering $0.52, resulting in a surprise of +10.64%. Over the last four quarters, the company has beaten consensus EPS estimates twice [12][13] Investment Considerations - Despite the negative Earnings ESP, the stock holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively. Investors should consider other factors beyond earnings results when making investment decisions [11][16]

Core Viewpoint - Wall Street anticipates flat earnings for Zurn Water (ZWS) in the upcoming quarter, with a consensus EPS estimate of $0.29, unchanged from the previous year, while revenues are expected to rise by 2.3% to $382.37 million [1][3]. Earnings Expectations - The stock may experience upward movement if actual earnings exceed expectations in the earnings report scheduled for April 22 [2]. - Conversely, if the earnings report falls short of estimates, the stock could decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.08% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - The Zacks Earnings ESP for Zurn Water is +2.34%, suggesting a higher likelihood of beating the consensus EPS estimate [11]. Earnings Surprise Prediction - The Most Accurate Estimate for Zurn Water is above the Zacks Consensus Estimate, indicating recent analyst optimism regarding the company's earnings prospects [10]. - A positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. Historical Performance - Zurn Water has consistently beaten consensus EPS estimates, achieving a surprise of +10.34% in the last reported quarter and surpassing estimates in all four of the last quarters [12][13]. Conclusion - Zurn Water is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings expectations when making investment decisions [16].

Wall Street expects a year-over-year increase in earnings on higher revenues when Range Resources (RRC) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 22. ...

Wall Street expects a year-over-year decline in earnings on higher revenues when NVR (NVR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lo ...

Company Performance - WaFd reported quarterly earnings of $0.65 per share, exceeding the Zacks Consensus Estimate of $0.60 per share, but down from $0.73 per share a year ago, representing an earnings surprise of 8.33% [1] - The company posted revenues of $179.79 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.38%, compared to year-ago revenues of $171.99 million [2] - Over the last four quarters, WaFd has surpassed consensus EPS estimates three times and topped consensus revenue estimates only once [2] Stock Performance - WaFd shares have declined approximately 24.1% since the beginning of the year, while the S&P 500 has decreased by 10.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $194.36 million, and for the current fiscal year, it is $2.48 on revenues of $755.03 million [7] Industry Outlook - The Zacks Industry Rank for Banks - West is currently in the bottom 46% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Solventum (SOLV) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 13.24%.For the last reported quarter, S ...

Reinsurance Group of America, Incorporated (RGA) shares are trading at a discount to the Zacks Life Insurance industry. Its forward price-to-book value of 1.2X is lower than the industry average of 1.83X, the Finance sector’s 4.05X and the Zacks S&P 500 Composite’s 7.89X. The life insurer has a Value Score of A.The insurer has a market capitalization of $13.09 billion. The average volume of shares traded in the last three months was 0.5 million. Shares of Sun Life Financial Inc. (SLF) and Primerica, Inc. (P ...

Group 1: Earnings Performance - BioXcel Therapeutics reported a quarterly loss of $3.57 per share, which was better than the Zacks Consensus Estimate of a loss of $4.36, representing an earnings surprise of 18.12% [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The revenue for the quarter ended December 2024 was $0.37 million, exceeding the Zacks Consensus Estimate by 144%, although it was slightly down from $0.38 million a year ago [2] Group 2: Stock Performance and Outlook - BioXcel Therapeutics shares have declined approximately 63.6% since the beginning of the year, contrasting with the S&P 500's decline of 2.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$2.72 on revenues of $0.3 million, and for the current fiscal year, it is -$16.32 on revenues of $3.51 million [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which BioXcel Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]